Adaptation to intermittent hypoxia restricts nitric oxide overproduction and prevents beta-amyloid toxicity in rat brain

Nitric Oxide - Biology and Chemistry

Volumn 23, Issue 4, 2010, Pages 289-299

  Goryacheva, Anna V ^a   Kruglov, Sergey V ^a,b   Pshennikova, Maya G ^a   Smirin, Boris V ^a   Malyshev, Igor Yu ^a,b   Barskov, Igor V ^c   Viktorov, Iljya V ^c   Downey, H Fred ^d   Manukhina, Eugenia B ^a,d  

^a INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^b A I EVDOKIMOV MOSCOW STATE UNIVERSITY OF MEDICINE AND DENTISTRY   (Russian Federation)

^c RESEARCH CENTER OF NEUROLOGY   (Russian Federation)

^d UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Adaptation; Alzheimer's disease; Beta amyloid; Intermittent hypoxia; Nitric oxide; NO synthase

Indexed keywords

3 NITROTYROSINE; AMYLOID BETA PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; HIPPOCAMPUS; HYPOXIA; INTERMITTENT HYPOXIA; MALE; MEMORY; NERVE DEGENERATION; NONHUMAN; OLIVARY NUCLEUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SLOT BLOT HYBRIDIZATION; WESTERN BLOTTING;

ADAPTATION, PHYSIOLOGICAL; AMYLOID BETA-PEPTIDES; ANIMALS; ANOXIA; BRAIN; MALE; NERVE DEGENERATION; NITRATES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITES; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR;

RATTUS;

EID: 77958154457     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.niox.2010.08.005     Document Type: Article

References (73)

1. Mallet R.T., Ryou M.-G., Manukhina E.B., Downey H.F. Intermittent hypoxic conditioning of canine myocardium: robust protection against ischemia-reperfusion injury. Adaptation Biology and Medicine: Health Potentials 2008, 59-78. Narosa Publishers, New Delhi. L. Lukyanova, N. Takeda, P.K. Singal (Eds.).
2. Mallet R.T., Ryou M.-G., Manukhina E.B., Downey H.F. Beta-adrenergic signaling and ros: pivotal roles in intermittent, normobaric hypoxia-induced cardioprotection. Intermittent Hypoxia: From Molecular Mechanisms to Clinical Applications 2008, 189-212. Nova Science Publishers, Hauppauge. L. Xi, T.V. Serebrovskaya (Eds.).
3. Serebrovskaya T.V., Manukhina E.B., Smith M.L., Downey H.F., Mallet R.T. Intermittent hypoxia: cause of or therapy for systemic hypertension?. Exp. Biol. Med. 2008, 233:627-650.
4. Manukhina E.B., Lapshin A.V., Meerson F.Z. Adaptation to intermittent hypoxia prevents disorders of endothelium-dependent relaxation and fall of blood pressure in experimental myocardial infarction. Hypox. Med. J. 1994, 1:15-18.
5. Pshennikova M.G., Manukhina E.B., Sazontova T.G., Prodius P.A., Golantsova N.E., Malyshev I.Yu., Pshennikova M.G., Pshennikova M.G. Molecular mechanisms of adaptation to environmental factors: new achievements of the Meerson school. Adaptation Biology and Medicine. vol. 2 1999, 199-213. Narosa Publishers, Delhi. B.B. Pandolf, N. Takeda, P.K. Singal (Eds.).
6. Krushinskiǐ A.L., Reutov V.P., Kuzenkov V.S., Sorokina E.G., Koshelev V.B., Fadiukova O.E., Baǐder L.M., Kuropteva Z.V., Zhumambaeva T.T., Komissarova L.Kh., Riasina T.V., Kositsyn N.S., Pinelis V.G. Nitric oxide is involved in the protective effects of short-term adaptaion to hypoxia in the course of stress-induced disorders in Krushinsky-Molodkina rats. Izv. Akad. Nauk. Ser. Biol. 2007, 3:329-335. (in Russian).
7. Maresová D., Jandová K., Bortelová J., Trojan S., Trnková B. Functional and morphological changes of the brain in rats exposed to intermittent hypobaric hypoxia after the repetitive magnesium administration. Prague Med. Rep. 2005, 106:61-69.
8. Meerson F.Z., Isabaeva V.A., Ivanshina A.Z. Acceleration of the rate of elaboration and degree of retention of conditioned reflexes in animals adapted to altitude hypoxia. Dokl. Akad. Nauk. SSSR 1972, 202:982-984. (in Russian).
9. Meerson F.Z. Essentials of Adaptive Medicine: Protective Effects of Adaptation 1994, Hypoxia Medical Ltd., Moscow.
10. López-Ramos J.C., Yi P.J., Eleore L., Madroñal N., Rueda A., Delgado-García J.M. Classical eyeblink conditioning during acute hypobaric hypoxia is improved in acclimatized mice and involves Fos expression in selected brain areas. J. Appl. Physiol. 2007, 103:1479-1487.
11. Jung M.E., Simpkins J.W., Wilson A.M., Downey H.F., Mallet R.T. Intermittent hypoxia conditioning prevents behavioral deficit and brain oxidative stress in ethanol-withdrawn rats. J. Appl. Physiol. 2008, 105:510-517.
12. Bernaudin M., Nedelec A.S., Divoux D., MacKenzie E.T., Petit E., Schumann-Bard P. Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes. Erythropoietin and VEGF, in the adult mouse brain. J. Cereb. Blood Flow Metab. 2002, 22:393-403.
13. Sharp F.R., Ran R., Lu A., Tang Y., Strauss K.I., Glass T., Ardizzone T., Bernaudin M. Hypoxic preconditioning protects against ischemic brain injury. NeuroRx 2004, 1:26-35.
14. Samoilenkova N.S., Gavrilova S.A., Koshelev V.B. Protective effect of hypoxic and ischemic preconditioning in rat brain local ischemia. Dokl. Biol. Sci. 2007, 414:183-184.
15. Prass K., Scharff A., Ruscher K., Lowl D., Muselmann C., Victorov I., Kapinya K., Dirnagl U., Meisel A. Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke 2003, 34:1981-1986.
16. Gulyaeva N.V., Stepanichev M.V., Onifriev M.V., Sergeev I.V., Mitrokhina O.S., Moiseeva Yu.V., Tkatchouk E.N. Interval hypoxia training prevents oxidative stress in striatum and locomotor disturbances in a rat model of parkinsonism. Progress in Alzheimer's and Parkinson's Diseases 1998, 717-723. Plenum Press, New York. A. Fisher, I. Hanln, M. Yoshida (Eds.).
17. Gauthier S., Scheltens P. Can we do better in developing new drugs for Alzheimer's disease?. Alzheimers Dement 2009, 5:489-491.
18. Mattson M.P. Neuroprotective signaling and the aging brain: take away my food and let me run. Brain Res. 2000, 886:47-53.
19. Mahendra N., Arkin S. Effects of four years of exercise, language, and social interventions on Alzheimer discourse. J. Commun. Disord. 2003, 36:395-422.
20. Swaab D.F., Dubelaar E.J., Scherder E.J., Van Someren E.J., Verwer R.W. Therapeutic strategies for Alzheimer disease: focus on neuronal reactivation of metabolically impaired neurons. Alzheimer Dis. Assoc. Disord. 2003, 17:S114-S122.
21. Pshennikova M.G., Popkova E.V., Pokidyshev D.A., Khomenko I.P., Zelenina O.M., Kruglov S.V., Manukhina E.B., Shimkovich M.V., Goriacheva A.V., Malyshev Iu.I. The effects of adaptation to hypoxia on the resistance to neurodegenerative disorders in the brain of rats of different genetic strains. Vestn. Ross. Akad. Med. Nauk. 2007, 2:50-55. (in Russian).
22. Manukhina E.B., Pshennikova M.G., Goryacheva A.V., Khomenko I.P., Mashina S.Yu., Pokidyshev D.A., Malyshev I.Yu. Role of nitric oxide in prevention of cognitive disorders in neurodegenerative brain injuries in rats. Bull Exp. Biol. Med. 2008, 146:391-395.
23. Manukhina E.B., Goriacheva A.V., Barskov I.V., Viktorov I.V., Guseva A.A., Pshennikova M.G., Khomenko I.P., Mashina S.Yu., Pokidyshev D.A., Malyshev I.Yu. Prevention of the brain neurodegeneration in rats with experimental Alzheimer's disease by adaptation to hypoxia. Ross. Fiziol. Zh. Im. I M Sechenova. 2009, 95:706-715. (in Russian).
24. 2425-35 in rat nucleus basalis induces behavioral dysfunctions impairs learning and memory and disrupts cortical cholinergic innervation. Behav. Brain Res. 1998, 90:133-145.
25. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, Sydney.
26. van der Zee E.A., Douma B.R., Bohus B., Luiten P.G. Passive avoidance training induces enhanced levels of immunoreactivity for muscarinic acetylcholine receptor and coexpressed PKC gamma and MAP-2 in rat cortical neurons. Cereb. Cortex 1994, 4:376-390.
27. Harkany T., De Jong G.I., Soós K., Penke B., Luiten P.G.M., Gulya K. β-Amyolois(1-42) affects cholinergic but not parvalbumin-containing neurons in the septal cortext of the rat. Brain Res. 1995, 698:270-274.
28. Clippingdale A.B., Wade J.D., Barrow C.J. The amyloid-beta peptide and its role in Alzheimer's disease. J. Pept. Sci. 2001, 7:227-249.
29. Aslan M., Ozben T. Reactive oxygen and nitrogen species in Alzheimer's disease. Curr. Alzheimer Res. 2004, 1:111-119.
30. Bertoni-Freddari C., Fattoretti P., Casoli T., Di Stefano G., Balietti M., Giorgetti B., Perretta G. Neuronal apoptosis in Alzheimer's disease: the role of age-related mitochondrial metabolic competence. Ann. NY Acad. Sci. 2009, 1171:18-24.
31. Kirsch M., Korth H.G., Sustmann R., De Groot H. The pathobiochemistry of nitrogen dioxide. Biol. Chem. 2002, 383:389-399.
32. Augusto O., Bonini M.G., Amanso A.M., Linares E., Santos C.C., De Menezes S.L. Nitrogen dioxide and carbonate radical anion: two emerging radicals in biology. Free Radic. Biol. Med. 2002, 32:841-859.
33. Pfeiffer S., Lass A., Schmidt K., Mayer B. Protein tyrosine nitration in mouse peritoneal macrophages activated in vitro and in vivo: evidence against an essential role of peroxynitrite. FASEB J. 2001, 15:2355-2364.
34. Brennan M.L., Wu W., Fu X., Shen Z., Song W., Frost H., Vadseth C., Narine L., Lenkiewicz E., Borchers M.T., Lusis A.J., Lee J.J., Lee N.A., Abu-Soud H.M., Ischiropoulos H., Hazen S.L. A tale of two controversies: defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice and the nature of peroxidase-generated reactive nitrogen species. J. Biol. Chem. 2002, 277:17415-17427.
35. Souza J.M., Daikhin E., Yudkoff M., Raman C.S., Ischiropoulos H. Factors determining the selectivity of protein tyrosine nitration. Arch. Biochem. Biophys. 1999, 371:169-178.
36. Gow A.J., Duran D., Malcolm S., Ischiropoulos H. Effects of peroxynitrate-induced protein modifications on tyrosine phosphorylation and degradation. FEBS Lett. 1996, 385:63-65.
37. Castegna A., Thongboonkerd V., Klein J.B., Lynn B., Markesbery W.R., Butterfield D.A. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J. Neurochem. 2003, 85:1394-1401.
38. Cenini G., Sultana R., Memo M., Butterfield D.A. Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer's disease. J. Cell Mol. Med. 2008, 12:987-994.
39. Butterfield D.A., Reed T.T., Perluigi M., De Marco C., Coccia R., Keller J.N., Markesbery W.R., Sultana R. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res. 2007, 1148:243-248.
40. Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S., Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 1997, 17:2653-2657.
41. Wallace M.N., Geddes J.G., Farquhar D.A., Masson M.R. Nitric oxide synthase in reactive astrocytes adjacent to β-amyloid plaques. Exp. Neurol. 1997, 144:266-272.
42. de la Monte S.M., Lu B.X., Sohn Y.K., Etienne D., Kraft J., Ganju N., Wands J.R. Aberrant expression of nitric oxide synthase III in Alzheimer's disease: relevance to cerebral vasculopathy and neurodegeneration. Neurobiol. Aging 2000, 21:309-319.
43. Lüth H.J., Holzer M., Gärtner U., Staufenbiel M., Arendt T. Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology. Brain Res. 2001, 913:57-67.
44. Gabbott P.L., Bacon S.J. Localisation of NADPH diaphorase activity and NOS immunoreactivity in astroglia in normal adult rat brain. Brain Res. 1996, 714:135-144.
45. Förstermann U., Kleinert H. Nitric oxide synthase expression and expressional control of the three isoforms. Naunyn Schmiedeberg's Arch. Pharmacol. 1995, 352:351-364.
46. Aguilera P., Chánez-Cárdenas M.E., Floriano-Sánchez E., Barrera D., Santamaría A., Sánchez-González D.J., Pérez-Severiano F., Pedraza-Chaverrí J., Jiménez P.D. Time-related changes in constitutive and inducible nitric oxide synthases in the rat striatum in a model of Huntington's disease. Neurotoxicology 2007, 28:1200-1207.
47. Fernández-Vizarra P., Fernández A.P., Castro-Blanco S., Encinas J.M., Serrano J., Bentura M.L., Muñoz P., Martínez-Murillo R., Rodrigo J. Expression of nitric oxide system in clinically evaluated cases of Alzheimer's disease. Neurobiol. Dis. 2004, 15:287-305.
48. Lüth H.J., Münch G., Arendt T. Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Res. 2002, 953:135-143.
49. Davies C.A., Mann D.M., Sumpter P.Q., Yates P.O. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J. Neurol. Sci. 1987, 78:151-164.
50. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
51. De Kosky S.T., Scheff S.W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol. 1990, 27:457-464.
52. Braak H., Rüb U., Schultz C., Del Tredici K. Vulnerability of cortical neurons to Alzheimer's and Parkinson's diseases. J. Alzheimers Dis. 2006, 9(3 Suppl.):35-44.
53. Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., DeLong M.R. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 1981, 10:122-126.
54. Stuiver B.T., Douma B.R., Bakker R., Nyakas C., Luiten P.G. In vivo protection against NMDA-induced neudegeneration by MK-801 and nimodipine: combined therapy and temporal course of protection. Neurodegeneration 1996, 5:153-159.
55. Nishimura A., Fujiwara S., Mizoi Y., Tatsuno Y. Morphometric, pathologic studies of the brain in autopsied cases of Alzheimer-type Dementia. Nihon Hoigaku Zasshi 1992, 46:141-151.
56. Boyd-Kimball D., Sultana R., Poon H.F., Lynn B.C., Casamenti F., Pepeu G., Klein J.B., Butterfield D.A. Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer's disease. Neuroscience 2005, 132:313-324.
57. Harkany T., O'Mahony S., Keijser J., Kelly I.P., Kónya C., Borostyánkoi Z.A., Görcs T.J., Zarándi M., Penke B., Leonard B.E., Luiten P.G. Beta-amyloid(1-42)-induced cholinergic lesions in rat nucleus basalis bidirectionally modulate serotonergic innervation of the basal forebrain and cerebral cortex. Neurobiol. Dis. 2001, 8:667-678.
58. OMahony S., Harkany T., Rensink A.A., Abrahám I., De Jong G.I., Varga J.L., Zarándi M., Penke B., Nyakas C., Luiten P.G., Leonard B.E. Beta-amyloid-induced cholinergic denervation correlates with enhanced nitric oxide synthase activity in rat cerebral cortex: reversal by NMDA receptor blockade. Brain Res. Bull. 1998, 45:405-411.
59. Cammermeyer J. The importance of avoiding Dark Neurons in experimental neuropathology. Acta Neuropathol. 1961, 1:245-270.
60. Manukhina E.B., Malyshev I.Yu. Role of free NO and NO stores in protective effects of adaptation to hypoxia. Adaptation Biology and Medicine. vol. 4: New Concepts 2005, 82-94. Narosa Publishing House, New Delhi. P.K. Singal, N. Takeda (Eds.).
61. Manukhina E.B., Downey H.F., Mallet R.T. Role of nitric oxide in cardiovascular adaptation to intermittent hypoxia. Exp. Biol. Med. 2006, 231:343-365.
62. Malyshev I.Yu., Zenina T.A., Golubeva L.Yu., Saltykova V.A., Manukhina E.B., Mikoyan V.D., Kubrina L.N., Vanin A.F. NO-dependent mechanisms of adaptation to hypoxia. Nitric Oxide 1999, 3:105-113.
63. Abu-Soud H.M., Wang J., Rousseau D.L., Fukuto J.M., Ignarro L.J., Stuehr D.J. Neuronal nitric oxide synthase self-inactivates by forming a ferrous-nitrosyl complex during aerobic catalysis. J. Biol. Chem. 1995, 270:22997-23006.
64. Manukhina E.B., Vanin A.F., Markov K.M., Malyshev I.Yu. Formation and role of nitric oxide stores in adaptation to hypoxia. Adv. Med. Biol. 2006, 578:35-40.
65. Manukhina E.B., Vanin A.F., Malyshev I.Yu., Mallet R.T., Downey H.F. Intermittent hypoxia-induced cardio- and vasoprotection: Role of NO stores. Intermittent Hypoxia: From Molecular Mechanisms To Clinical Applications 2009, 113-146. Nova Science Publishers, Hauppauge. L. Xi, T.V. Serebrovskaya (Eds.).
66. Mashina S.Y., Aleksandrin V.V., Goryacheva A.V., Vlasova M.A., Vanin A.F., Malyshev I.Yu., Manukhina E.B. Adaptation to hypoxia prevents disturbances in cerebral blood flow during neurodegenerative process. Bull. Exp. Biol. Med. 2006, 142:169-172.
67. Lin A.M., Chen C.F., Ho L.T. Neuroprotective effect of intermittent hypoxia on iron-induced oxidative injury in rat brain. Exp. Neurol. 2002, 176:328-335.
68. El'chaninova S.A., Koreniak N.A., Smagina I.V., Pinegin L.E., Varshavskiǐ B.Ia. Intermittent hypoxia in the treatment of dyscirculatory encephalopathy. Zh Nevrol Psikhiatr Im S S Korsakova 2002, 102:29-32. (in Russian).
69. Zhu L.L., Zhao T., Li H.S., Zhao H., Wu L.Y., Ding A.S., Fan W.H., Fan M. Neurogenesis in the adult rat brain after intermittent hypoxia. Brain Res. 2005, 1055:1-6.
70. Soucek T., Cumming R., Dargusch R., Maher P., Schubert D. The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide. Neuron 2003, 39:43-56.
71. Neubauer J.A. Physiological and pathophysiological responses to intermittent hypoxia. J. Appl. Physiol. 2001, 90:1593-1599.
72. 2-regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF-1. J. Appl. Physiol. 2004, 96:1173-1177.
73. Walshe T.E., D'Amore P.A. The role of hypoxia in vascular injury and repair. Annu. Rev. Pathol. 2008, 3:15-43.